Art

J-GLOBAL ID：201702286420003511   Reference number：17A1559482

Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial

エクセナチド週1回投与とパーキンソン病におけるプラセボ:無作為化二重盲検プラセボ対照試験【Powered by NICT】

Author (18)： Athauda Dilan (Sobell Department of Motor Neuroscience, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK) ,  Maclagan Kate (Comprehensive Clinical Trials Unit, University College London, London, UK) ,  Skene Simon S (Comprehensive Clinical Trials Unit, University College London, London, UK) ,  Bajwa-Joseph Martha (Comprehensive Clinical Trials Unit, University College London, London, UK) ,  Letchford Dawn (Comprehensive Clinical Trials Unit, University College London, London, UK) ,  Chowdhury Kashfia (Comprehensive Clinical Trials Unit, University College London, London, UK) ,  Hibbert Steve (Comprehensive Clinical Trials Unit, University College London, London, UK) ,  Budnik Natalia (Leonard Wolfson Experimental Neuroscience Centre, London, UK) ,  Zampedri Luca (Leonard Wolfson Experimental Neuroscience Centre, London, UK) ,  Dickson John (Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK) ,  Li Yazhou (Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA) ,  Aviles-Olmos Iciar (Sobell Department of Motor Neuroscience, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK) ,  Warner Thomas T (Queen Square Brain Bank, London, UK) ,  Limousin Patricia (Sobell Department of Motor Neuroscience, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK) ,  Lees Andrew J (Sobell Department of Motor Neuroscience, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK) ,  Greig Nigel H (Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA) ,  Tebbs Susan (Comprehensive Clinical Trials Unit, University College London, London, UK) ,  Foltynie Thomas (Sobell Department of Motor Neuroscience, University College London Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, UK)
Material： Lancet
Volume： 390  Issue： 10103  Page： 1664-1675  Publication year： 2017 
JST Material Number： B0673A  ISSN： 0140-6736  CODEN： LANCA  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Exenatide, a glucagon-like pep...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1559482&from=J-GLOBAL&jstjournalNo=B0673A") }}

Thesaurus term： *Parkinson's disease ,  pathophysiology ,  evaluation criterion ,  patient ,  *placebo ,  *double blind test ,  subcutaneous administration ,  receptor ,  reliability (property) ,  therapy ,  adverse reaction ,  catecholamine ,  primary amine
Semi thesaurus term： 有害事象 ,  スコア ,  UPDRS ,  重症度 , 【Automatic Indexing@JST】

JST classification (1)： Treatment for metabolic diseases,nutritional diseases.  (GD05030F)

Substance index (1)： Dopamine

Terms in the title (5)： エクセナチド ,  週1回投与 ,  パーキンソン病 ,  プラセボ ,  二重盲検